Insilico Medicine doses first patient in Phase III GENESIS-IPF-3 trial of rentosertib for IPF

• Insilico Medicine launched a Phase III study of rentosertib in idiopathic pulmonary fibrosis, dosing the first patient on Sept. 9, 2026.
• The trial will test whether once-daily treatment over 52 weeks improves outcomes versus placebo, aiming to confirm earlier clinical signals.
• Results were previously presented in Phase IIa, described as showing promising improvement in lung function; Phase III results will be presented in the future.
• Management guided to a three- to four-year path from Phase III start to potential regulatory approval under favorable conditions.
• Insilico reported $106 million revenue in H1 2026, swinging to an adjusted net profit above $51 million, citing deal-driven funding capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609092030PR_NEWS_USPR_____CN43654) on September 10, 2026, and is solely responsible for the information contained therein.